MYRIAD GENETICS INC

For the period ended Mar 31, 2025. Filed May 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

MYGN$5.67-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets as of and (unaudited)

Condensed Consolidated Balance Sheets (unaudited)

	March 31,2025	December 31,2024
ASSETS
Current assets:
Cash and cash equivalents	$91.8	$102.4
Trade accounts receivable	120.4	121.2
Inventory	28.3	27.5
Prepaid taxes	14.3	16.4
Prepaid expenses and other current assets	32.4	30.5
Total current assets	287.2	298.0
Operating lease right-of-use assets	53.4	55.0
Property, plant, and equipment, net	114.0	117.4
Intangibles, net	257.5	262.4
Goodwill	286.3	286.3
Other assets	7.7	8.5
Total assets	$1,006.1	$1,027.6
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$28.1	$32.3
Accrued liabilities	112.1	119.0
Current maturities of operating lease liabilities	10.9	12.8
Total current liabilities	151.1	164.1
Unrecognized tax benefits	1.4	32.7
Long-term debt	59.3	39.6
Noncurrent operating lease liabilities	87.4	87.9
Other long-term liabilities	2.0	2.2
Total liabilities	301.2	326.5
Commitments and contingencies
Stockholders’ equity:
Common stock, 92.2 and 91.3 shares outstanding at March 31, 2025 and December 31, 2024, respectively	0.9	0.9
Additional paid-in capital	1,461.5	1,457.8
Accumulated other comprehensive loss	(0.6)	(0.8)
Accumulated deficit	(756.9)	(756.8)
Total stockholders' equity	704.9	701.1
Total liabilities and stockholders’ equity	$1,006.1	$1,027.6

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.